PL2248517T3 - Stężone formulacje farmaceutyczne stabilizujące komórki tuczne - Google Patents
Stężone formulacje farmaceutyczne stabilizujące komórki tuczneInfo
- Publication number
- PL2248517T3 PL2248517T3 PL09006294T PL09006294T PL2248517T3 PL 2248517 T3 PL2248517 T3 PL 2248517T3 PL 09006294 T PL09006294 T PL 09006294T PL 09006294 T PL09006294 T PL 09006294T PL 2248517 T3 PL2248517 T3 PL 2248517T3
- Authority
- PL
- Poland
- Prior art keywords
- concentrated
- pharmaceutical formulations
- mast cell
- cell stabilizing
- stabilizing pharmaceutical
- Prior art date
Links
- 210000003630 histaminocyte Anatomy 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000087 stabilizing effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09006294.4A EP2248517B1 (en) | 2009-05-08 | 2009-05-08 | Concentrated mast cell stabilizing pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2248517T3 true PL2248517T3 (pl) | 2014-08-29 |
Family
ID=40934943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09006294T PL2248517T3 (pl) | 2009-05-08 | 2009-05-08 | Stężone formulacje farmaceutyczne stabilizujące komórki tuczne |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9198859B2 (pl) |
| EP (1) | EP2248517B1 (pl) |
| JP (1) | JP5863641B2 (pl) |
| ES (1) | ES2457442T3 (pl) |
| PL (1) | PL2248517T3 (pl) |
| WO (1) | WO2010128111A1 (pl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3067047B1 (en) | 2005-12-08 | 2022-04-20 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| PL2852391T3 (pl) | 2012-05-21 | 2022-04-11 | Insmed Incorporated | Układy do leczenia infekcji płuc |
| US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| EP3563849A3 (en) | 2012-10-25 | 2020-02-12 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
| US10124066B2 (en) | 2012-11-29 | 2018-11-13 | Insmed Incorporated | Stabilized vancomycin formulations |
| WO2015002703A1 (en) * | 2013-05-23 | 2015-01-08 | Aztherapies, Inc | Methods for delivering cromolyn |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| CN110305095A (zh) | 2013-10-22 | 2019-10-08 | 综合医院公司 | 色甘酸衍生物以及成像和治疗的相关方法 |
| ES2792682T3 (es) * | 2014-02-10 | 2020-11-11 | Respivant Sciences Gmbh | Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos |
| PL3104853T3 (pl) * | 2014-02-10 | 2020-05-18 | Respivant Sciences Gmbh | Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych |
| LT3466432T (lt) | 2014-05-15 | 2020-12-28 | Insmed Incorporated | Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti |
| US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| WO2018044942A1 (en) | 2016-08-31 | 2018-03-08 | Patara Pharma, LLC | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
| JP2019524865A (ja) | 2016-08-31 | 2019-09-05 | ザ ジェネラル ホスピタル コーポレイション | 神経変性疾患と関連する神経炎症におけるマクロファージ/ミクログリア |
| EP3522983A4 (en) * | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS |
| KR101861163B1 (ko) * | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | 안과용 약학 조성물 |
| JP7202376B2 (ja) | 2017-07-20 | 2023-01-11 | エーゼットセラピーズ, インコーポレイテッド | クロモリンナトリウムおよびイブプロフェンの粉末製剤 |
| EP3773505B1 (en) | 2018-03-30 | 2026-04-29 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| JP7449275B2 (ja) | 2018-05-02 | 2024-03-13 | インスメッド インコーポレイテッド | リポソーム薬物製剤の製造方法 |
| AU2019299347A1 (en) | 2018-07-02 | 2021-01-21 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and alpha-lactose |
| MX2021006869A (es) | 2018-12-10 | 2021-07-02 | Massachusetts Gen Hospital | Esteres de cromolin y usos de los mismos. |
| CN110960514A (zh) * | 2019-12-23 | 2020-04-07 | 杭州百诚医药科技股份有限公司 | 一种吸入用复方多索茶碱溶液及其制备方法 |
| WO2021207060A1 (en) | 2020-04-06 | 2021-10-14 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
| WO2022146914A1 (en) | 2020-12-28 | 2022-07-07 | The General Hospital Corporation | Cromolyn derivatives and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2167300B (en) * | 1984-11-23 | 1988-11-23 | Fisons Plc | Formulations |
| GB8520133D0 (en) | 1985-08-10 | 1985-09-18 | Fisons Plc | Mixtures |
| DE3700379A1 (de) | 1987-01-08 | 1988-07-21 | Mann Gerhard Chem Pharm Fab | Konservierte augentropfen mit einem gehalt an cromoglicinsaeure |
| EP0413583A3 (en) | 1989-08-18 | 1991-07-17 | Dey Laboratories; Inc. | Clear, stable cromolyn formulation |
| GB9214390D0 (en) * | 1992-07-07 | 1992-08-19 | Fisons Plc | Formulations |
| DE19539532C2 (de) | 1995-10-24 | 1999-02-25 | Mann Gerhard Chem Pharm Fab | Ophthalmisches Cromoglicat-Gelpräparat |
| US6004949A (en) | 1995-12-27 | 1999-12-21 | Showa Yakuhin Kako Co., Ltd. | Aqueous composition containing cromoglycic acid |
| US20040045546A1 (en) * | 2002-09-05 | 2004-03-11 | Peirce Management, Llc | Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use |
| DE102005038619A1 (de) | 2005-08-16 | 2007-02-22 | Pari GmbH Spezialisten für effektive Inhalation | Inhalationstherapievorrichtung mit einer Ampulle für die Bevorratung eines zu vernebelnden Medikaments |
| US8263645B2 (en) | 2006-02-03 | 2012-09-11 | Pari Pharma Gmbh | Disodium cromoglycate compositions and methods for administering same |
| MX2008010222A (es) * | 2006-02-10 | 2008-10-17 | Pari Pharma Gmbh | Antibioticos nebulizados para terapia de inhalacion. |
| EP2030644A1 (en) | 2007-08-31 | 2009-03-04 | PARI Pharma GmbH | Aerosols for sinunasal drug delivery |
| DE102007056462B4 (de) | 2007-11-23 | 2011-10-27 | Pari Pharma Gmbh | Einwegampulle für eine Vorrichtung zur Erzeugung von Aerosolen |
-
2009
- 2009-05-08 PL PL09006294T patent/PL2248517T3/pl unknown
- 2009-05-08 EP EP09006294.4A patent/EP2248517B1/en not_active Not-in-force
- 2009-05-08 ES ES09006294.4T patent/ES2457442T3/es active Active
-
2010
- 2010-05-06 JP JP2012509043A patent/JP5863641B2/ja not_active Expired - Fee Related
- 2010-05-06 WO PCT/EP2010/056197 patent/WO2010128111A1/en not_active Ceased
-
2011
- 2011-11-08 US US13/291,488 patent/US9198859B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010128111A1 (en) | 2010-11-11 |
| US20120118991A1 (en) | 2012-05-17 |
| JP2012526084A (ja) | 2012-10-25 |
| JP5863641B2 (ja) | 2016-02-16 |
| ES2457442T3 (es) | 2014-04-25 |
| US9198859B2 (en) | 2015-12-01 |
| EP2248517A1 (en) | 2010-11-10 |
| EP2248517B1 (en) | 2014-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2248517T3 (pl) | Stężone formulacje farmaceutyczne stabilizujące komórki tuczne | |
| HUS2000009I1 (hu) | Kétrétegû tabletta készítmények | |
| SMT202300282T1 (it) | Formulazioni farmaceutiche altamente concentrate | |
| IL225415A0 (en) | Electrolytic formulations | |
| ZA201106050B (en) | Dye-polymers formulations | |
| BRPI1016228A2 (pt) | formulações de eletrólito compatibilizadas | |
| ZA201200719B (en) | Pharmaceutical formulation | |
| EP2512490A4 (en) | S-ADENOSYLMETHIONINE FORMULATIONS WITH INCREASED BIOAVAILABILITY | |
| IL219264A0 (en) | Docetaxel formulations with lipoic acid | |
| IL269369A (en) | The vehicles are improved | |
| GB0919210D0 (en) | Formulations | |
| GB0909134D0 (en) | Cathode | |
| IL217887A0 (en) | Concentrated polypeptide formulations with reduced viscosity | |
| AP2013006687A0 (en) | Formulations | |
| PT2568970T (pt) | Formulações farmacêuticas estáveis contendo um anti-histamínico | |
| EP2473168A4 (en) | PHARMACEUTICAL FORMULATIONS FOR INDIBULIN | |
| IL217390A0 (en) | Formulations | |
| PL2261444T3 (pl) | Maszt | |
| AP2013006689A0 (en) | Formulations | |
| HU0900086V0 (en) | Mast | |
| GB0917744D0 (en) | Formulations | |
| GB201012047D0 (en) | Pharmaceutical formulations | |
| GB201012046D0 (en) | Pharmaceutical formulations | |
| GB0914489D0 (en) | Improved formulations | |
| AU2009905633A0 (en) | Formulations |